Manufacturer record
SAI Parenterals Ltd. D1&D4: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
3 batches manufactured by SAI Parenterals Ltd. D1&D4 (Telangana) were declared Not of Standard Quality between August 2025 and September 2025. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: 24AM19, Amikacin Sulphate Injection IP 500mg/2ml (exp Nov 2026). CDL, Kolkata (CDSCO lab) found it not of standard quality: Sterility', 'Particulate Matter' and "Description". Listed in the September 2025 alert.
Records by type
3 records linked to SAI Parenterals Ltd. D1&D4 in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Amikacin Sulphate Injection IP 500mg/2ml | Batch 24AM19Mfg Dec 2024 · Exp Nov 2026 | Sterility', 'Particulate Matter' and "Description".Description | CDL, KolkataCDSCO lab | Sep 2025 |
| Iron Sucrose Injection USP 100 mg/ 5 ml | Batch 24RSO6Mfg Feb 2024 · Exp Jan 2026 | pHpH | CDL, KolkataCDSCO lab | Aug 2025 |
| Clindamycin Injection IP | Batch 24CL02Mfg Sep 2024 · Exp Aug 2026 | Particulate Matter and Description.Description | CDL, KolkataCDSCO lab | Aug 2025 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.